Website
Now part of www.vaxart.com
Biota Holdings was an antiviral drug development company with a history of successful R&D in respiratory diseases. It merged with U.S.-based Nabi Biopharmaceuticals to form Biota Pharmaceuticals (now Vaxart Inc).
Biota developed Relenza®, one of the first neuraminidase inhibitors for influenza treatment, in collaboration with GlaxoSmithKline. Its inhaled delivery and antiviral action represented a major advancement in flu therapeutics.
